arzoxifene hydrochloride

DRUG5 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Eli Lilly and Company, University of Kansas Medical Center, The Cleveland Clinic

Conditions

Breast CancerEndometrial CancerHereditary Breast/Ovarian Cancer (brca1, brca2)Ovarian CancerPrimary Peritoneal Cavity Cancer

Phase 1

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

CompletedNCT00005886

University of Kansas Medical CenterBreast Cancer

Start: 2000-07-31End: 2002-08-31Updated: 2017-01-13

Phase 2

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

CompletedNCT00003670

Eli Lilly and CompanyOvarian Cancer, Primary Peritoneal Cavity Cancer

Start: 1998-10-31End: 2001-01-31Updated: 2012-06-07

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

CompletedNCT00003669

Eli Lilly and CompanyEndometrial Cancer

Start: 1998-11-30End: 2001-04-30Updated: 2012-06-07

Hormone Therapy in Treating Women With Breast Cancer

CompletedNCT00003428

Memorial Sloan Kettering Cancer CenterBreast Cancer

Start: 1998-05-31End: 2001-06-30Target: 114Updated: 2013-06-24

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

CompletedNCT00253539

The Cleveland ClinicBreast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)

Start: 2002-01-31End: 2005-04-30Updated: 2011-04-13